ERBB2 and breast cancer: An immunohistochemistry (IHC) profile based on the degree of expression of estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (HER2) similarly identifies subgroups of BC patients who will have similar gene expression patterns and clinical outcomes [3-5].